AxoGen (NASDAQ:AXGN) Director Joseph Tyndall Sells 3,500 Shares of Stock

AxoGen, Inc. (NASDAQ:AXGN) Director Joseph Tyndall sold 3,500 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $49.70, for a total value of $173,950.00. Following the transaction, the director directly owned 10,650 shares in the company, valued at approximately $529,305. This represents a 24.73% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

AxoGen Trading Up 2.5%

AXGN stock traded up $1.18 during mid-day trading on Friday, reaching $48.28. 550,066 shares of the stock traded hands, compared to its average volume of 1,085,818. The company has a debt-to-equity ratio of 0.07, a quick ratio of 5.04 and a current ratio of 6.60. AxoGen, Inc. has a one year low of $15.27 and a one year high of $52.91. The stock has a market capitalization of $2.60 billion, a PE ratio of -71.00 and a beta of 1.16. The business has a 50-day moving average price of $45.14 and a two-hundred day moving average price of $40.00.

AxoGen (NASDAQ:AXGN) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.12. AxoGen had a negative net margin of 13.36% and a negative return on equity of 8.90%. The firm had revenue of $69.73 million during the quarter, compared to analyst estimates of $67.10 million. Equities research analysts expect that AxoGen, Inc. will post -0.45 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have commented on AXGN shares. Wall Street Zen raised AxoGen from a “hold” rating to a “buy” rating in a research report on Sunday, July 26th. HC Wainwright lifted their target price on AxoGen from $50.00 to $53.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Jefferies Financial Group reiterated a “buy” rating and set a $55.00 price objective on shares of AxoGen in a research note on Wednesday, July 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AxoGen in a research report on Wednesday, August 26th. Finally, Canaccord Genuity Group boosted their price target on AxoGen from $50.00 to $55.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $51.56.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Commonwealth Equity Services LLC grew its position in AxoGen by 1.8% during the 4th quarter. Commonwealth Equity Services LLC now owns 21,473 shares of the medical equipment provider’s stock worth $703,000 after purchasing an additional 371 shares during the period. PNC Financial Services Group Inc. boosted its stake in shares of AxoGen by 6.2% in the first quarter. PNC Financial Services Group Inc. now owns 8,943 shares of the medical equipment provider’s stock worth $296,000 after buying an additional 525 shares during the last quarter. Nykredit A S purchased a new stake in shares of AxoGen in the second quarter worth about $30,000. Arax Advisory Partners grew its holdings in AxoGen by 362.4% during the fourth quarter. Arax Advisory Partners now owns 1,045 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 819 shares during the period. Finally, Brooklyn Investment Group raised its position in AxoGen by 4.2% during the fourth quarter. Brooklyn Investment Group now owns 20,568 shares of the medical equipment provider’s stock valued at $688,000 after acquiring an additional 823 shares in the last quarter. Hedge funds and other institutional investors own 80.29% of the company’s stock.

About AxoGen

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.